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Abstract
Background: The use of Lamivudine in chronic hepatitis B (CHB) is well known, however the
reported rate of HBeAg sero-conversion and its durability post-treatment have varied
considerably. We undertook the present study to study the effect of Lamivudine on HBeAg loss
and seroconversion rates in Indian patients of CHB in relation to frequency, predictors and
durability.
Methods: We treated 60 patients of e antigen positive CHB (with active viral replication and
ongoing necro-inflammatory activity) with Lamivudine. They were followed up by monthly
aminotransferases, and 3 monthly HBeAg and anti-HBe. Those who attained HBeAg sero-
conversion were advised to discontinue Lamivudine after 6 months and followed up every 3
months thereafter, to see for relapse. Treatment was given for maximum of 3 years if not sero-
converted.
Results: The annual incremental loss of HBeAg in patients receiving Lamivudine was 25 (41.6%) at
end of 1st year, 33 (55%) at 2nd year and 35 (58.3%) at 3rd year. The corresponding rates for full
sero-conversion were 17/60 (28.6%), 22/60 (36.6%) and 24/60 (40%) in the 3 years. HBeAg loss
correlated with increased pre-therapy ALT levels (p = 0.002) and decreased pretreatment HBV-
DNA levels (p = 0.004). The presence of cirrhosis had no influence on the rate of HBeAg loss.
Relapse occurred in 35% (7/20) post-treatment at median time of 6 months.
Conclusion: Indian patients showed a higher rate of HBeAg sero-conversion in the first year of
Lamivudine treatment. This correlated with baseline ALT and inversely with HBV-DNA levels.
Relapse rate after treatment was high and occurred soon after stopping treatment.
Background
Hepatitis B virus infects more than 300 million people
worldwide, contributing to debilitating illness and death,
and more than 75% of those affected are of Asian origin
[1]. Chronically infected persons with viral replication are
at highest risk for progressive liver disease and it is
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estimated that up to 25% of persons with chronic hepati-
tis B virus infection will die prematurely of cirrhosis or
hepatocellular carcinoma. Cirrhosis and hepatocellular
carcinoma account for more than 50% of deaths in Asian
men with chronic Hepatitis B infection [2].
The risk of chronicity after acute HBV infection is low in
immuno-competent adults and is reported to be less than
5%[3]. However, the natural history of HBV infection dif-
fers between Asian and Western patients. Asians usually
become infected perinatally, rarely have an acute hepati-
tis-like clinical syndrome but almost invariably remain
chronically infected and run substantial risk for develop-
ing cirrhosis and hepatocellular carcinoma. Western
patients who are usually infected in adult life by percuta-
neous or sexual exposure, typically have an acute hepati-
tis-like clinical illness, clear the virus and rarely become
chronically infected [4,5]. Chronically infected persons
with evidence of active viral replication are at highest risk
for progressive liver disease. Cirrhosis develops in 15 to 20
% of them within 5 years, even if histologic liver damage
is initially mild [6]. HBeAg seroconversion, which can
occur spontaneously or post-treatment, is associated with
a substantial reduction in the risk of liver failure [7]. Spon-
taneous sero-conversion occurs only in 7 to 20 % per year
[8].
Interferon -alfa was the first drug specifically licensed to
treat chronic Hepatitis B. The efficacy of Interferon-alfa
was found to be variable, but a meta-analysis showed that
33% receiving it lost HBeAg compared with 12% of
untreated controls [9]. Interferon-alfa was least effective in
Asian patients [10]. It has to be given by injection and has
potential dose-limiting side effects. Patients with liver cir-
rhosis often deteriorated on initiating treatment [7].
Enthusiasm with Interferon for treatment for chronic hep-
atitis B therefore waned with the wide availability and use
of Lamivudine.
Lamivudine, an oral nucleoside analogue, inhibits viral
DNA replication. In doses of 100 mg/day in adults (1.5
mg/Kg/day in children), the median suppression of serum
HBV-DNA is greater than 98% in most patients during
treatment [11]. It produces rapid decrease in serum HBV-
DNA and aminotransferase levels, improves liver histol-
ogy and enhances the rate of HBeAg loss compared with
placebo treatment [12,13]. The virologic end points of
treatment have been the sustained disappearance of
serum HBV DNA by a conventional hybridization assay
and either the disappearance of hepatitis B e antigen from
serum [HBeAg loss] or the loss of HBeAg accompanied by
the detection of anti-HBe [HBeAg sero-conversion]
[11,12]. The proportion of patients achieving HBeAg sero-
conversion after 12 months of Lamivudine treatment
[100 mg/day] has ranged between 16% and 18% in West-
ern and Asian studies [11-13]. Several workers have
shown pre-treatment high serum ALT and low serum
HBV-DNA levels to be independently associated with
increased rate of HBeAg loss and sero-conversion when
treated with Lamivudine [13,14].
The safety of Lamivudine has led to the suggestion that
continuous therapy may be beneficial, particularly in
patients who do not lose HBeAg. Extended treatment with
Lamivudine beyond 1 year has shown good results in var-
ious studies with results showing an incremental response
in HBeAg sero-conversion rate [15,16]. The study by
Leung NW et al showed sero-conversion rates of 22% after
1 year, increasing to 29% after 2 years and 40% after 3
years [16]. A major limitation of chronic therapy however
is the development of viral resistance, marked virologi-
cally by rise in HBV DNA levels despite continuation of
therapy and clinically by increases in serum transaminases
[11,12,15,17]. Lamivudine induced HBeAg seroconver-
sion was reported to be durable by several Western stud-
ies, 80 to 90%[12] and 73%[18]. However, studies in
Asian countries show that relapse rates are much higher
post treatment, 37.5% at 1 year [19] and 45.8%[20].
It has been observed that Hepatitis B virus may behave dif-
ferently in different geographic regions [19,21]. This may
be due to some host factors or to the viral genotypic dif-
ferences [21]. Therefore it is important for each country to
determine to determine its own rate and pattern of sero-
conversion following treatment of chronic hepatitis B.
The aims of the present study was to study the effect of
Lamivudine on chronic hepatitis B in Indian patients with
regard to 1) rate of seroconversion and HBeAg loss 2) pre-
dictors of seroconversion 3) the durability of seroconver-
sion post treatment.
Methods
Patients
Sixty patients [50 men and 10 women, median age 40
years, range 4–80 years, cirrhosis 23] with HBeAg positive
chronic HBV infection who were started on Lamivudine
100 mg per day (1.5 mg/Kg/day in children) during the
time period from August 1998 to June 2001 were fol-
lowed up. All patients were positive for HBsAg for more
than six months, had active replicative status [HBeAg pos-
itive, AntiHBe negative and HBV-DNA positive by PCR
technique] with alanine aminotransferase levels that were
less than 10 times the upper limit of normal for at least the
previous 3 months. All had evidence of ongoing necro-
inflammatory activity either on liver biopsy (knodell
ishak score>4) or suggested by raised alanine aminotrans-
ferase levels. Cirrhosis was diagnosed on basis of clinical
[evidence of portal hypertension, liver decompensation],
biochemical, endoscopic [varices] and imaging [ultra-
sound] evidence. Patients were excluded if they had any ofBMC Gastroenterology 2005, 5:29 http://www.biomedcentral.com/1471-230X/5/29
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the following: previous antiviral treatment for hepatitis B;
immunomodulatory drugs or corticosteroids within 6
months before Lamivudine treatment; co infection with
hepatitis C virus or the human immunodeficiency virus;
or the presence of other types of liver disease.
The study was approved by the local ethics committee and
all patients provided informed consent before treatment.
Methods
Lamivudine was given at a dose of 100 mg/day during the
study period. Serum ALT was checked monthly and serum
HBeAg, anti-HBe [measured by the commercially availa-
ble ELISA kit; Organon Teknika] 3 monthly till serocon-
version. HBV DNA testing by the In-house PCR technique
was done to confirm viral suppression, initially at 3
months and then annually. It was also done at the time of
seroconversion or biochemical breakthrough. HBV-DNA
levels were done by Quantiplex branched DNA assay at
baseline and at 3 months. HBeAg seroconversion was
defined as disappearance of HBeAg and appearance of
anti-HBe antibody, while HBeAg loss was defined as dis-
appearance of HBeAg only. Viral breakthrough was iden-
tified on the basis of ALT rise (greater than 2 × upper limit
of normal) with re-emergence of HBV-DNA positivity (by
PCR) and detectable levels of HBV DNA. HBeAg serocon-
version was confirmed by repeat testing after 3 months.
Lamivudine was continued for 6 months after seroconver-
sion was achieved or for maximum of 3 years. Thereafter
post treatment monitoring in those who had serocon-
verted continued by monthly ALT and 3 monthly HBeAg,
anti- HBe. This was done to look for relapse, which was
defined as re-emergence of HBV DNA positivity by PCR
technique and/or HBeAg positivity after Lamivudine was
stopped post seroconversion.
Statistics
The baseline factors evaluated were age, sex, BMI, weight,
ALT, HBV DNA levels and presence of cirrhosis. Data were
expressed as median (range) or mean+/- SD. For statistical
significance, nominal variables were analyzed by Chi
square test with Yates correction. For numerical variables
Wilcoxon Rank Sum Test was used, as the data was not
expected to have a Gaussian distribution. A p value of <
0.05 was taken as significant.
Results
Patient population
Sixty patients who received Lamivudine were followed up.
All of them completed at least 1 year of treatment. In the
second year 4 patients who had not seroconverted, did
not come for follow up and similarly in the 3 rd year 6
patients dropped out. [See table 1 for baseline characteris-
tics] The majority, 50 [83.3%], were men, and median age
was 40 years [range 4–80 years]. The mode of transmis-
sion of HBV was unknown in most [61.7%] with blood
transfusion history being present in 11.7% and history of
hemodialysis in 13.3%. Elevated ALT was present in 50
[83.3%] of the 60 patients. The median ALT level was 72
Table 1: Base-line Characteristics of the Patients
Age (yr)
Median 40
Range 4–80
Male sex (%)
Weight (kg) 83.3
Median 58.5
Range 14–101
Route of HBV acquisition (%)
Blood Transfusion 11.7
Renal Dialysis 13.3
Sexual 5
Perinatal 3.3
Others 5
Unknown 61.7
BMI (kg/m2)
Median 22.8
Range 16.4–29.5
ALT (U/L)
Abnormal (%) 83.3
Median 72
Range 27–394
Median × ULN 1.8
HBV-DNA (mEq/ml)
Mean 920
Range 0.8–4500
Cirrhosis (%) 38.33
Cumulative HBeAg seroconversion and loss in 60 patients Figure 1
Cumulative HBeAg seroconversion and loss in 60 patients.
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U/L [range 27 to 394] and median HBV DNA level 920
[range: 0.8–4500] mEq/ml. The median × Upper limit of
normal of ALT was 1.8. Cirrhosis was present in 23
[38.3%] of the patients.
HBeAg response
Sero-conversion of HBeAg to anti HBe occurred in 17 of
60 patients (28.33%) at the end of first year and incre-
mentally rose to 36.6%(22/60) by second year and to
40%(24/60) by third year as shown in Figure 1. Of all
sero-conversions maximum occurred in the first year (17/
24) 71%, 21% in the 2nd year and only 8% in the 3rd
year. The rate of HBeAg loss was 41.66%(25/60) in first
year and incrementally rose to 58.3% (35/60) by third
year of treatment. Similar to that seen for seroconversion,
maximum loss of HBeAg occurred in the 1st year (71.42%)
as compared to 2nd and 3rd years of treatment (22.8% and
5.71 % respectively). Onset of seroconversion occurred at
a mean of 10.17 months after starting treatment.
Pretreatment factors influencing HBeAg loss
The association of age, sex, weight, BMI, baseline ALT,
baseline HBV-DNA level and presence of cirrhosis with
HBeAg loss was analyzed. [See table 2] Only baseline ALT
and HBV DNA level were associated significantly with
HBeAg clearance, with median ALT among those who lost
their HBeAg being 94 U/L compared with median ALT in
those who did not, 45 U/L (p = 0.002). Likewise the
median HBV DNA level was 111.3 mEq/ml among those
who lost their HBeAg as compared to that in those who
did not, 958 mEq/ml (p = 0.004). Table 3 depicts the fre-
quency of HBeAg loss and seroconversion according to
baseline ALT level. HBeAg response rates increased with
increase in level of pretreatment ALT. Among patients
with pretreatment ALT levels greater than 1 to 2 times the
ULN, HBeAg loss occurred in 50%, which increased to
70% among those with ALT levels greater than 2 to 5
times the ULN. The rate of HBeAg loss was highest among
those with ALT levels greater than 5 times ULN, occurring
in 80 %. Similar trends were observed with HBeAg sero-
conversion, though seroconversion occurred less fre-
quently than HBeAg loss. Figure 2 depicts the HBeAg
seroconversion rates year wise according to baseline ALT
levels. After 1 year, 15% (3 of 20) of patients with baseline
serum ALT >1–2 × ULN, 40% (8 of 20) with ALT>2 – 5 ×
ULN and 60% (6 of 10) had achieved seroconversion,
increasing to 30% (6 of 20), 55% (11 of 20) and 70% (7
of 10) respectively after 3 years of treatment.
ALT normalization and HBV-DNA levels
Alanine aminotransferase normalization occurred in 56%
(28/50) of patients with elevated baseline ALT levels. This
occurred more significantly in those who cleared their
HBeAg (71.8%) than those who did not (27.7%), p = 0.02
[see table 2] Among the 24 who seroconverted, in 22
(91%), ALT normalization occurred in the first year. HBV
DNA levels became undetectable within 3 months after
initiating Lamivudine treatment in 19 out of 21 patients
(90.4%) in whom it was done. The 2 patients in whom it
was still detectable, one of whom had chronic renal fail-
ure and was on maintenance peritoneal dialysis, did not
attain seroconversion on long-term treatment.
Follow up and relapse
Median follow-up of 8 months [Range 3–18 months] was
done in 20 patients who had seroconverted and stopped
Lamivudine. Two patients did not come for follow up
Table 2: Pre-treatment Variables Influencing HBeAg Loss
Variable HBeAg 
Loss 
(n = 35)
No HBeAg 
Loss 
(n = 25)
p value
Age (years) 37.5 44 ns
Sex
Male 29 21 ns
Female 6 4
Weight (Kg) 60 55 ns
BMI 23.1 22.7 ns
Median ALT (U/L) 94 45 0.002
Range 32–394 27–254
Median HBV-DNA (mEq/ml) 111.3 958 0.004
Range 0.8–4500 4.2–3500
Cirrhosis
Present 13 10 ns
Absent 22 15
ALT Normalization
Yes 23 5 0.02(df = 1)
No 9 13
Table 3: HBeAg Seroconversion and Loss by Pretreatment ALT 
Level
HbeAg Seroconversion HBeAg Loss
ALT Level Number % Number %
<= 1 × ULN 0/10 - 3/10 30
>1-<=2 × ULN 6/20 30 10/20 50
>2-<=5 × ULN 11/20 55 14/20 70
> 5 × ULN 7/10 70 8/10 80
Total 24/60 40 35/60 58.3BMC Gastroenterology 2005, 5:29 http://www.biomedcentral.com/1471-230X/5/29
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after serconversion and in the other two, minimum follow
up of 3 months was not available at time of analysis.
Relapse was seen in 7 patients (35%), which occurred at a
median of 6 months after stopping treatment [Range 3–8
months].
Breakthrough
Breakthrough infection [i.e. re- emergence of DNA posi-
tivity, increase in viral load and increase in ALT] during
treatment occurred in 6 patients out of the 25 (24%) who
did not achieve HBeAg loss. These 6 had undetectable
DNA levels initially at 3 months after starting Lamivu-
dine. The onset of viral breakthrough was at 10 months in
2, 15 months in 1, 18 months in 1, and at 27 months in
2. None of these patients achieved seroconversion on
long-term Lamivudine and were persistently HBeAg
positive.
Discussion
The present study in Indian patients show high serocon-
version rates in the first year (28.6%), reaching 40% at
end of 3 years. The first year rate is higher than previous
Western and Asian studies but by the 3rd year the cumula-
tive rate becomes similar to that mentioned by Leung NW
et al [16]. The rate of HBeAg loss, cumulatively rising from
36.6% in the first year to 58.3% by third year is also more
than that showed by Perrillo RP et al, 25% in the first year
[13] and Dienstag JL et al, 32%[12]. These results clearly
indicate that Indian patients have higher HBeAg loss and
seroconversion rates in the first year of treatment but the
cumulative response seen on extended treatment is not
much and by 3 years, the seroconversion rate reaches only
40%, which is mentioned in the previous studies. Sero-
conversion rates were further enhanced in patients with
elevated pretreatment ALT, reaching 60% by 3 years in
those with baseline ALT>2 × ULN. The 1st year seroconver-
sion rate in these patients is higher than that seen by
Leung NW et al (27%) but again; by the 2nd and 3rd years
the rates become similar [16]. It is also seen that the max-
imum percentage of seroconversions occurred in the first
year (70.8% of all seroconversions), which is more than
that seen by Leung et al, 56.5% [16]. It is not clear why the
seroconversion rate in Indian patients, as seen in the
present study is different from the previous published
Western and Asian rates. The baseline median ALT con-
centration in the present study (1.8 × ULN) is comparable
to that in previous studies, [14,16] and less than reported
by Perrillo et al (2.2 × ULN)[13]. Also taking only those
with elevated ALT, the 1st year seroconversion rate in the
in the present study is still higher than that mentioned in
previous studies [12,16]. The mean HBV DNA level (920
mEq/ml) is actually more than that seen by Lau et al (587
mEq/ml)[15]. Therefore differences in these baseline
characteristics that influence seroconversion are not the
reason for the higher seroconversion rate seen. Differ-
ences in the HBV genotype can account for changing pat-
terns of HBV response to treatment, in different
geographic locations and is mentioned later.
The effect that progressively higher levels of pretreatment
ALT had on HBeAg loss was striking. Previous studies with
Lamivudine have shown that there is a significant correla-
tion between pretherapy ALT levels and HBeAg serocon-
version as well as HBeAg loss. Among patients with
pretreatment ALT 2–5 × ULN, 70% achieved HBeAg loss
and at the highest level (> 5 × ULN), 80% experienced
HBeAg loss. This is much more than seen by Chien RN et
al -64%[14] and Perrillo RP et al; 56%[13], but similar to
that seen by Liaw YF et al; 80%[23]. As the number of
patients with ALT levels greater than 5 times the ULN was
relatively small, a larger sample size would be required for
a more accurate estimate. As ALT elevations in patients
with chronic hepatitis B are the results of T-cell -mediated
hepatocytolysis, [24] the level of ALT elevation reflects the
level of T-cell immune response of the patients to HBV. As
also shown by the present analysis, antiviral agents like
Lamivudine are more effective, in terms of HBeAg sero-
conversion, in patients who have mounted an ongoing
immune response to HBV. The high HBeAg seroconver-
sion in patients with high baseline ALT levels seems to the
result of a concerted effort of (1) the immune -mediated
killing of the hepatocytes harboring cccDNA by the anti-
viral defenses of the host, and (2) the potent direct antivi-
ral effect of Lamivudine and the enhanced CD-4
responses resulting from Lamivudine therapy. This sug-
gests that alternative treatment strategies need to be
HBeAg Seroconversion Year wise According to Baseline ALT Figure 2
HBeAg Seroconversion Year wise According to Baseline 
ALT.
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defined for patients in the immune tolerance phase or
with a low anti-HBV immune response. The present study
also showed significant correlation between low baseline
HBV-DNA levels and HBeAg loss. This has been shown in
previous studies [11-15]. That the other baseline factors
like age, sex, BMI and weight had no effect on seroconver-
sion has also been seen in previous studies [13,14].
Some studies have shown that the presence of cirrhosis
could be a predictor of HBeAg sero-conversion [13,14]. As
the number of patients with cirrhosis was high (38 %) in
the present study as compared to previous studies, we had
a doubt whether it was contributing to the high sero-con-
version rates seen. But on analysis, in the present study,
presence of cirrhosis had no statistical significant correla-
tion with HBeAg loss.
Normalization of ALT was seen to occur more signifi-
cantly in patients who had HBeAg loss than in those with-
out, as seen in previous studies [15,16,23]. A disturbing
finding in the present study was the high relapse rate of
35% post treatment. This is in variance with Western stud-
ies showing durability of HBeAg seroconversion post
treatment [12,18]. However studies from South East Asia
have reported similar high relapse rates [19,20]. The cause
of the high relapse rate is not clear. It may be caused by
immune tolerance, which is caused by a long-standing
viral infection [25,26]. It has been suggested that Lamivu-
dine treatment can restore immune response to HBV with
reduction in viral load [27]. However, long-standing
infections in vertically transmitted patients may make this
immune response incomplete [25,26]. Even in patients
with spontaneous HBeAg seroconversion, frequent
relapses were observed in patients with long-standing
HBV infection [28]. The duration of additional Lamivu-
dine treatment after HBeAg seroconversion and pretreat-
ment HBV-DNA levels are 2 independent predictive
factors for relapse [19]. Although Lamivudine can inhibit
viral replication, it cannot eliminate covalently closed cir-
cular DNA (cccDNA) in hepatocytes [29]. Studies using in
vitro and in vivo model systems have shown that chronic
infection is maintained by the cccDNA in hepatocytes
[29]. The minimum half-life of the infected cells was esti-
mated to exceed 10 to 100 days. Therefore it was suggested
that prolonged treatment over 12 months might be
needed till viral clearance, otherwise the chances for
relapse [30].
Although the HBeAg seroconversion rate was high in our
study, it was not durable. This observation quite contrasts
with results in Western countries, in which the therapeu-
tically induced seroconversion is usually maintained
[12,18]. Similar high relapse rates were seen in the study
by Song et al in Korean patients [19]. The cause of the high
relapse rate after HBeAg seroconversion is not clear. It may
be caused by immune tolerance, which is caused by a
long-standing viral infection [25,26]. It has been
suggested that lamivudine therapy can restore immune
response to HBV with reduction of viral load. However,
long standing infections in vertically transmitted patients
may make this immune response incomplete [25,26].
Even in patients with spontaneous HBeAg seroconver-
sion, frequent relapses were observed in patients with
long-standing HBV infection [28]. Therefore, it can be
suggested that HBeAg seroconversion does not necessarily
guarantee prolonged suppression of HBV infection in
those endemic areas in which perinatal transmissions are
common.
Viral breakthrough was seen in 6 patients. In all of these
six, HBV DNA had become undetectable initially at 3
months. All six did not achieve seroconversion with Lam-
ivudine treatment. Sequencing of HBV genome for YMDD
mutations was not performed to confirm viral resistance
emerging. Resistance to Lamivudine typically develops
after 6 months of treatment and is associated with muta-
tions in the highly conserved catalytic region of the HBV
polymerase gene [15]. Previous studies show the develop-
ment of resistance in a high proportion of patients
[31,32]. In studies from Asia, resistance was reported to
occur in 17% of patients after 1 year [11], 26% after 2
years [33] and 49% after 3 years of treatment [34]. In the
Indian study by Wakil et al, frequency of emergence of
YM5521/VDD mutations was 29% and presence of nor-
mal ALT and low levels of HBV-DNA did not exclude the
existence of resistant mutants [35]. Therefore only looking
at biochemical and virologic breakthrough, as in the
present study will miss out on identifying the emergence
of viral resistance in most. The majority of patients in
these studies, who developed resistance, still had bio-
chemical and virologic evidence of improvement in the
liver disease [23,33,34].
The genetic heterogeneity of the HBV genome has been
established and seven genotypes (A to G) can be classified,
based on comparison of complete HBV genomes [36].
The geographic distribution of these genotypes is
heterogeneous with genotypes A and D being more com-
mon in India [39]. Studies are now coming out showing
differences in the natural history and response to treat-
ment among the various genotypes. Studies have shown
that genotype C is associated with more severe liver injury
as compared with genotype B [37]. In a study by Yuen MF
et al it was seen that genotype C was associated with lower
rate of HBeAg seroconversion whereas genotype B had
earlier onset of seroconversion [21]. HBV genotype has
also been related to interferon treatment. In a study on
German subjects, interferon induced HBeAg seroconver-
sion was higher among patients with genotype A than
those with genotype D [40]. Another report from TaiwanBMC Gastroenterology 2005, 5:29 http://www.biomedcentral.com/1471-230X/5/29
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found that the rate of HBeAg loss was significantly higher
in patients with genotype B compared with C [38]. A third
study in HBeAg negative patients found that patients with
genotype A responded better than genotype D (70% vs.
40%) [41]. With regards to Lamivudine, reports are less
and only one study mentions better response of genotype
B as compared to genotype C [42]. Therefore geographic
differences in the natural history and response to treat-
ment of chronic hepatitis B could be explained by the gen-
otypic variations of HBV between different geographic
regions. This may explain the higher early sero-conversion
rates seen in this present study as compared to other West-
ern and Asian studies. Also whether any host genetic fac-
tor could be influencing the rate of seroconversion has to
be ascertained. Future work has to address these issues.
Conclusion
The results show that the HBeAg seroconversion rate in
the first year in Indian patients is higher than that pub-
lished from previous Western and Asian studies, but by
three years the seroconversion rates become similar. Max-
imum seroconversion occurs in the first year with not
much additional benefit on continuing treatment into the
2nd and 3rd years. Pretreatment ALT and HBV DNA levels
were significant predictors of HBeAg loss. Relapse rates
after treatment were high and were comparable to previ-
ous Asian studies. Future work has to done to elucidate
the cause for the geographic variations in the rates of
HBeAg seroconversion, especially with regard to influence
of genotypes and any host genetic factors identified.
Abbreviations
CHB: chronic hepatitis B
HBeAg: hepatitis B e antigen
ALT: alanine amino-transferase
HBV-DNA: hepatitis B virus DNA
Competing interests
The author(s) declare that they have no competing
interests.
Authors' contributions
GA: Participated in the study design, collection of data
and drafting the manuscript
CSB, KS, TSN: Participated in the study design and collec-
tion of data
GC: Conceived the study, participated in its design, coor-
dination, drafting the manuscript
Acknowledgements
Uday C Ghoshal for statistical analysis help
References
1. Maynard JE: Hepatitis B: global importance and need for
control.  Vaccine 1990, 8:S18-S20.
2. Beasley RP, Hwang LY, Lin CC, Chien CS: Hepatocellular Carci-
noma and Hepatitis B: a prospective study of 22,707 men in
Taiwan.  Lancet 1981, 2:1129-33.
3. Seef B, Beebe GW, Hoofnagle JH: A serological follow up of the
1942 epidemic of post-vaccination hepatitis in the United
States Army.  N Engl J Med 1987, 316:965.
4. Beasley RP, Hwang GY: Postnatal infectivity of hepatitis B sur-
face antigen carrier mothers.  J Infect Dis 1983, 147:185-90.
5. Margoli HS, Alter MJ, Hadler SC: Hepatitis B: evolving epidemi-
ology and implications for control.  Semin Liver Dis 1991,
11:84-92.
6. Maddrey WC: Hepatitis B: an important public health issue.  J
Med Virol 2000, 61:362-366.
7. Niederau C, Heintges T, Lange S, Goldman G, Mohr L, Haussinger D:
Long-term follow up of HBeAg positive patients treated with
IFN-alpha for Chronic Hepatitis B.  N Eng J Med 1996,
334:1422-1427.
8. Lok A, Lai CL, Wu P, Leung EKY, Lam TS: Spontaneous hepatitis
B e antigen to antibody seroconversion and reversion in Chi-
nese patients with chronic hepatitis B virus infection.  Gastro-
enterology 1987, 92:1839-1843.
9. Wong DKH, Cheung AM, O'Rourke , Naylor CD, Detsky AS, Heath-
cote J: Effect of alpha-interferon treatment in patients with
hepatitis B e antigen-positive chronic hepatitis B: a meta-
analysis.  Ann Intern Med 1993, 119:312-23.
10. Lok ASF, Wu PC, Lai CL, Lau JY, Leung EK, Wong LS, Ma OC, Lauder
IJ, Ng CP, Chung HT: A controlled trial of interferon with or
without prednisone priming for chronic hepatitis B.  Gastroen-
terology 1992, 102:2091-2097.
11. Lai C-L, Chien R-N, Nancy WY, Chang TT, Guan R, Tai DI, Ng KY,
Wu PC, Dent JC, Barber J, Stephenson SL, Gray F: A one year trial
of Lamivudine for chronic hepatitis B.  N Engl J Med 1998,
339:61-68.
12. Dienstag JL, Schiff ER, Wright TL, Perillo RP, Hann HW, Goodman Z,
Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA: Lam-
ivudine as initial treatment for chronic hepatitis B in the
United States.  N Engl J Med 1999, 341:1256-1263.
13. Perillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, Heath-
cote EJ, Brown NA, Atkins M, Woessner M, Gardner SD: Predictors
of HBeAg loss after Lamivudine treatment for Chronic Hep-
atitis B.  Hepatology 2002, 36:186-194.
14. Chien RN, Liaw Y-F, Atkins M: Pretreatment ALT level as a
determinant for Hepatitis B eAg seroconversion during
Lamivudine treatment in patients with Hepatitis B.  Hepatol-
ogy 1999, 30:770-774.
15. Lau DT-Y, Khokhar F, Doo E, Ghany MG, Herion D, Park Y, Kleiner
D, Schmid P, Condreay L, Gauthier J, Kuhns M, Liang TJ, Hoofnagle J:
Long term treatment of Chronic Hepatitis B with
Lamivudine.  Hepatology 2000, 32:828-834.
16. Leung NW, Lai C-L, Chang T-T, Guan R, Lee CM, Ng KY, Lim SG, Wu
PC, Dent JC, Edmondson S, Condreay L, Chien RN: Extended Lam-
ivudine treatment in patients with Chronic Hepatitis B
enhances HBeAg seroconversion rates: Results after 3 years
of treatment.  Hepatology 2001, 33:1527-1532.
17. Tassopoullous NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin
RD, Hawley S, Barber J, Condreay L, Gray DF: Efficacy of lamivu-
dine with patients with HBeAg -ve hepatitis B virus DNA
positive [precore mutant] Chronic Hepatitis B.  Hepatology
1999, 29:889-896.
18. Schiff E, Chancier J, Rowley K, Norkrans G, Perillo R, Tong M,
Crowther L: Durability of HBeAg seroconversion after Lami-
vudine monotherapy in phase II and III trial.  Hepatology 1998,
28:163A. (abstract 1)
19. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS: HBeAg seroconver-
sion after Lamivudine treatment is not durable in patients
with chronic hepatitis B in Korea.  Hepatology 2000, 32:803-6.
20. Lee CM, Ong GY, Lu SN, et al.: Durability of Lamivudine induced
HBeAg seroconversion for chronic hepatitis B patients with
acute exacerbation.  J Hepatol 2002, 32(5):669-74.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Gastroenterology 2005, 5:29 http://www.biomedcentral.com/1471-230X/5/29
Page 8 of 8
(page number not for citation purposes)
21. Man FY, Erwin S, He-Jun Y, Decraemer H, Lai CL: Significance of
hepatitis B genotype in acute exacerbation, HBeAg serocon-
version, and cirrhosis related complications and HCC.  Hepa-
tology 2003, 37:562-567.
22. Kao JH, Chen PJ, Lai MY, Chen DS: Hepatitis B genotypes corre-
late with clinical outcomes in patients with chronic hepatitis
B.  Gastroenterology 2000, 118:554-559.
23. Liaw YF, Leung NW, Chang T-T, Guan R, Tai DI, Ng KY, Chien RN,
Dent J, Roman L, Edmondson S, Condreay L, Chien RN: Effects of
extended Lam treatment in Asian patients with Chronic
Hepatitis B.  Gastroenterology 2000, 119:172-180.
24. Liaw YF, Tsai SL: Pathogenesis and significance of acute exac-
erbation and remission in patients with Chronic Hepatitis B
virus infection.  Viral Hep Rev 1997, 3:143-154.
25. Chisari FV, Ferrari : Hepatitis B virus immunopathogenesis.
Annu Rev Immunol 1995, 13:29-60.
26. Davis GL, Hoofnagle JH: Reactivation of chronic hepatitis B
infection.  Gastroenterology 1987, 92:2028-2031.
27. Boni C, Bertoletti A, Penn A, Cavalli A, Pilli M, Urbani S, Scognamiglio
P, Boehme R, Panebianco R, Fiaccadori F, Ferrari C: Lamivudine
treatment can restore T cell responsiveness in chronic hep-
atitis B.  J Clin Invest 1998, 102:968-975.
28. Davis GL, Hoofnagle JH, Waggoner JG: Spontaneous reactivation
of chronic hepatitis B virus infection.  Gastroenterology 1984,
86:230-235.
29. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC: Inhibition of
the replication of hepatitis B virus in vitro by 2' 3'-dideoxy-3'-
thiacytidine and related analogues.  Proc Natl Acad Sci USA 1991,
88:8495-8499.
30. Zeuzem S, deMan RA, Honkoop P, Roth W, Schalm S, Schmidt J:
Dynamics of hepatitis B virus infection in vivo.  J Hepatol 1997,
27:431-436.
31. Liaw YF, Chien R-N, Yeh C-T, Tsai S-L: Acute exacerbation and
hepatitis B virus clearance after emergence of YMDD motif
mutation during Lamivudine treatment.  Hepatology 1999,
30:567-572.
32. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dushieko GM, Har-
rison TJ: Selection of mutations in the hepatitis B virus
polymerase during treatment of transplant recepients with
Lamivudine.  Hepatology 1996, 24:711-713.
33. Liaw Y-F, Lai CL, Leung NW, Chang TT, Guan R, Tau DI, Ng KY,
Chien RN, Dent J, Roman L, Edmondson S, Condreay L, Chien RN:
Two year Lamivudine treatment in Chronic Hepatitis B
infection- results of a placebo controlled multicentre study
in Asia.  Gastroenterology 1998, 114:A1289.
34. Chang T-T, Lai CL, Liaw Y-F, Leung NWY, Guan R, Lim SG, Lee CM:
Enhanced HBeAg seroconversion rates in Chinese patients
on Lamivudine.  Hepatology 1999, 30:420A.
35. Wakil JM, Kazim SN, Khan CA, Raisuddin S, Parvez M, Guptan R,
Thakur V, Hasnain S, Sarin SK: Prevalence and treatment profile
of Mutations associated with Lamivudine treatment in
Indian patients with Chronic Hepatitis B in the surface and
Polymerase genes of HBV.  J Med Virol 2002, 68:311-318.
36. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF,
Rossau R: A new genotype of hepatitis B virus: complete
genomes and phylogenetic relatedness.  J Gen Virol 2000,
81:67-74.
37. Lindh M, Hannoun C, Dhillon AP, Norkrans G, Horal P: Core Pro-
moter mutations and genotypes in relation to viral replica-
tion and liver damage in East Asian hepatitis B virus carriers.
J Infect Dis 1999, 179:775-82.
38. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS: Hepatitis B genotypes
and the response to interferon therapy.  J Hepatol 2000,
33:998-1002.
39. Thakur V, Guptan RC, Kazim SN, Malhotra V, Sarin SK: Profile,
spectrum and significance of HBV genotypes in chronic liver
disease patients in the Indian subcontinent.  J Gastroenterol
Hepatol 2002, 17(2):165-170.
40. Erhardt A, Reineke U, Blondin D: Mutations of core promoter
and response to interferon treatment in chronic replicative
hepatitis B.  Hepatology 2000, 31:716-725.
41. Zhang X, Zoulim F, Habersetzer F: Analysis of hepatitis B virus
genotypes and pre-core region variability during IFN treat-
ment of HBe antigen negative CHB.  J Med Virol 1996, 48:8-16.
42. Kao JH, Liu CJ, Chen DS: Hepatitis B viral genotypes and lami-
vudine resistance.  J Hepatol 2002, 36:303-4.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-230X/5/29/pre
pub